Strata Oncology, a precision oncology company advancing molecular indications for cancer therapies, announced the completion of a $90 million Series C financing, bringing the company's total financing to over $130 million since the company's inception.

Wellington Management led the financing and was joined by other new investors including Cormorant Asset Management, Monashee Investment Management and Highside Capital Management. Strata Oncology's existing investors, including Pfizer Ventures, Merck Global Health Innovation Fund, Arboretum Ventures, Deerfield Management, Baird Capital and Renaissance Venture Capital Fund also participated in the financing.